Christopher Freeburn

Christopher Freeburn

InvestorPlace Writer

Christopher T. Freeburn has been a financial writer and editor for more than 10 years. He has worked at industry trade publications like Food Logistics, ChemicalWeek and Institutional Investor. His freelance articles have appeared in a variety of magazines, including Technology Review, Audubon and USA Weekend. He lives in Westchester County, just outside New York City.”

Recent Articles

Lockheed Martin Tops Forecasts, Raises Outlook

By Christopher Freeburn, InvestorPlace Writer

Lockheed Martin shook off the prospect of looming cuts in U.S. defense spending to raise its outlook for the year as it topped second-quarter profit estimates.

Lexmark Misses Q2 Estimates, Warns on Q3, Shares Dive

By Christopher Freeburn, InvestorPlace Writer

Lexmark announced second-quarter net income and revenue that fell short of expectations and warned that revenue would decline during the current quarter.

Monday Apple Rumors: Strong Interest in New iPhone

By Christopher Freeburn, InvestorPlace Writer

More consumers want the new iPhone; the new iPhone is already in production in China; and the new iPhone will have a smaller dock connector.

Novartis Wins Approval for Breast Cancer Drug

By Christopher Freeburn, InvestorPlace Writer

The FDA has granted approval for Novartis' drug Afinitor to be used as a treatment for breast cancer after it showed promise in clinical trials.

Nokia Brushes Off Moody’s Downgrade

By Christopher Freeburn, InvestorPlace Writer

Nokia officials said that Moody's recent two-notch downgrade of its credit rating would have a "limited" impact on the company.

Load More